<DOC>
	<DOCNO>NCT01440569</DOCNO>
	<brief_summary>This study evaluate safety tolerability cobicistat-boosted darunavir plus two fully active nucleoside analogue reverse transcriptase inhibitor HIV 1 infected , antiretroviral treatment-naive treatment-experienced adult darunavir ( DRV ) resistance-associated mutation . After Week 48 Visit , participant give option participate open-label rollover phase receive cobicistat attend visit every 12 week becomes commercially available , Gilead Sciences elect terminate development cobicistat .</brief_summary>
	<brief_title>Safety Efficacy Cobicistat-boosted Darunavir HIV Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Adult ≥ 18 year male nonpregnant female Ability understand sign write informed consent form General medical condition interfere assessment completion trial Treatment Naive : No prior use approve investigational antiretroviral drug length time OR Treatment Experienced : Stable antiretroviral regimen least 12 week prior screen Plasma HIV1 RNA level ≥ 1000 copies/mL Screening Screening genotype report show full sensitivity two nucleoside analogue reverse transcriptase inhibitor ( NRTIs ) darunavir resistanceassociated mutation Normal electrocardiogram ( ECG ) Hepatic transaminases ≤ 2.5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL Adequate hematologic function Serum amylase ≤ 2 × ULN serum lipase ≤ 3 × ULN Adequate renal function : Estimated glomerular filtration rate ≥ 80 mL/min Females childbearing potential must agree utilize protocolrecommended method contraception , nonheterosexually active , practice sexual abstinence vasectomize partner Screening throughout duration study period 30 day follow last dose study drug . Male subject must agree utilize protocolrecommended method contraception heterosexual intercourse Screening visit , throughout duration study 30 day follow discontinuation investigational medicinal product nonheterosexually active , practice sexual abstinence , vasectomize . Previous current use darunavir A new AIDSdefining condition diagnose within 30 day prior Screening Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Proven suspect acute hepatitis 30 day prior study entry Subjects receive drug treatment hepatitis C virus ( HCV ) , subject anticipate receive treatment HCV course study Have history ongoing active liver disease experience decompensated cirrhosis irrespective liver enzyme level Have implant defibrillator pacemaker Current alcohol substance use may interfere subject study compliance A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma Active , serious infection require parenteral antibiotic antifungal therapy within 30 day prior Baseline Participation clinical trial Any clinical condition prior therapy would make subject unsuitable study unable comply dose requirement . Subjects receive ongoing therapy medication , include drug use cobicistat , darunavir , investigator select NRTIs ; subject know allergy cobicistat tablet , darunavir tablet contraindication 2 NRTIs part regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Naïve</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>